Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Non-Hodgkin's Lymphoma treatment details. Biologic therapy. Columbia University Medical Center, New York, NY, United States



Survival: 16.9 months
   
Toxicity Grade: 4
   
Treatments: Biologic therapy
   
Drugs:
Country: United States
   
City/State/Province: New York, NY
   
Hospital: Columbia University Medical Center
   
Journal: Link
   
Date: 5/2014

Description:
Patients:
This phase 2 study involved 58 mantle cell lymphoma patients who were previously treated with bortezomib. The median patient age was 68 years years and 77.6% were male.

Treatment:
Patients were treated with the biologic therapy agent everolimus, an inhibitor of the mTOR protein that causes cancer cell death.

Toxicities:
The most severe toxicities were of grade 4 and included neutropenia, thrombocytopenia, and abdominal pain. Grade 3 fatigue and pneumonia were also reported.

Results:
The median overall survival was 16.9 months.

Support:
This study was supported by Novartis Pharmaceuticals.

Correspondence: Dr. Owen A. O’Connor; email: owenoconnor@columbia.edu

E-mail to a Friend Email Physician More Information